Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
Status:
Completed
Trial end date:
2013-05-14
Target enrollment:
Participant gender:
Summary
The aim of this study is to establish a dose-related effect of a selective 5-HT4 receptor
agonist compared to placebo on residual symptoms (regurgitation with or without heartburn) in
subjects with GERD who have persistent symptoms while on PPI therapy.